Home » Stocks » GRTX

Galera Therapeutics, Inc. (GRTX)

Stock Price: $6.64 USD -0.42 (-5.95%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
Market Cap 168.09M
Revenue (ttm) n/a
Net Income (ttm) -74.22M
Shares Out 24.98M
EPS (ttm) -173.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $6.64
Previous Close $7.06
Change ($) -0.42
Change (%) -5.95%
Day's Open 7.07
Day's Range 6.43 - 7.32
Day's Volume 179,677
52-Week Range 6.43 - 15.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propr...

1 month ago - GlobeNewsWire

MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propri...

5 months ago - GlobeNewsWire

Presented Promising Interim Data from Placebo-controlled P ilot Dismutase Mimetic SBRT Combination Trial for P ancreatic C ancer

5 months ago - GlobeNewsWire

MALVERN, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propri...

5 months ago - GlobeNewsWire

Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting

5 months ago - GlobeNewsWire

Interim d ata on first 19 patients released in ASTRO Annual Meeting late-breaker presentation abstract showed improvement in overall survival and multiple anti-cancer efficacy measures

5 months ago - GlobeNewsWire

MALVERN, Pa., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...

6 months ago - GlobeNewsWire

MALVERN, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...

7 months ago - GlobeNewsWire

Galera Therapeutics is a promising company backed by prestigious venture firms.

7 months ago - Seeking Alpha

Completed Enrollment of Randomized, Blinded, Placebo-controlled Trial of GC4419 in Combination with Radiotherapy in Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H20

8 months ago - GlobeNewsWire

MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop...

8 months ago - GlobeNewsWire

Topline safety and efficacy data to be reported in the second half of 2020 Topline safety and efficacy data to be reported in the second half of 2020

9 months ago - GlobeNewsWire

Retrospective analysis of patients with head and neck cancer treated in Phase 2b clinical trial of avasopasem manganese presented at ASCO 2020 Virtual Scientific Program Retrospective analysis of patien...

10 months ago - GlobeNewsWire

ROMAN Phase 3 Trial Topline Data Readout Guidance Updated to 2H21 Due to Impact of COVID-19

11 months ago - GlobeNewsWire

MALVERN, Penn., April 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, p...

11 months ago - GlobeNewsWire

MALVERN, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop...

1 year ago - GlobeNewsWire

-- Evaluates avasopasem manganese’s ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer -- -- Marks expansion of lead product candidate avasopasem manganese ...

1 year ago - GlobeNewsWire

About GRTX

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with ... [Read more...]

Industry
Biotechnology
IPO Date
Nov 7, 2019
Stock Exchange
NASDAQ
Ticker Symbol
GRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for GRTX stock is "Strong Buy." The 12-month stock price forecast is 19.60, which is an increase of 195.18% from the latest price.

Price Target
$19.60
(195.18% upside)
Analyst Consensus: Strong Buy